EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Juvenile polyposis syndrome in children: The impact of SMAD4 and BMPR1A mutations on clinical phenotype and polyp burden

Shlomi Cohen iD, Anat Yerushalmy-Feler, Isabel Rojas, Claudia Phen, David A Rudnick, Colleen B Flahive, Steven H Erdman, Ramit Magen-Rimon, Ivana Copova, Thomas Attard, Andrew Latchford, Warren Hyer

Journal of Pediatric Gastroenterology and Nutrition · 2024

DOI: 10.1002/jpn3.12257 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Shlomi Cohen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Tel Aviv Sourasky Medical Center, affiliated to the Faculty of Medicine, Pediatric Gastroenterology Institute, Dana-Dwek Children's Hospital, Tel Avi…. Hauptthemen laut MEDLINE: Smad4 Protein, Bone Morphogenetic Protein Receptors, Type I, Intestinal Polyposis, Phenotype. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ESPGHAN Networking Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

A constitutional disease‐causing variant (DCV) in the SMAD4 or BMPR1A genes is present in 40%–60% of patients with juvenile polyposis syndrome (JPS). The aim of this study was to characterize the clinical course and polyp burden in children with DCV‐positive JPS compared to DCV‐negative JPS.

Methods

Demographic, clinical, genetic, and endoscopic data of children with JPS were compiled from eight international centers in the ESPHGAN/NASPGHAN polyposis working group.

Results

A total of 124 children with JPS were included: 69 (56%) DCV‐negative and 55 (44%) DCV‐positive (53% SMAD4 and 47% BMPR1A ) with a median (interquartile range) follow‐up of 4 (2.8–6.4) years. DCV‐positive children were diagnosed at an older age compared to DCV‐negative children [12 (8–15.7) years vs. 5 (4–7) years, respectively, p < 0.001], had a higher frequency of family history of polyposis syndromes (50.9% vs. 1.4%, p < 0.001), experienced a greater frequency of extraintestinal manifestations (27.3% vs. 5.8%, p < 0.001), and underwent more gastrointestinal surgeries (16.4% vs. 1.4%, p = 0.002). The incidence rate ratio for the development of new colonic polyps was 6.15 (95% confidence interval 3.93–9.63, p < 0.001) in the DCV‐positive group compared to the DCV‐negative group, with an average of 12.2 versus 2 new polyps for every year of follow‐up. There was no difference in the burden of polyps between patients with SMAD4 and BMPR1A mutations.

Conclusions

This largest international cohort of pediatric JPS revealed that DCV‐positive and DCV‐negative children exhibit distinct clinical phenotype. These findings suggest a potential need of differentiated surveillance strategies based upon mutation status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smad4 ProteinBone Morphogenetic Protein Receptors, Type IIntestinal PolyposisPhenotypeMutationNeoplastic Syndromes, HereditaryHumansChildMaleFemaleAdolescentChild, PreschoolFollow-Up Studies

Stichwörter der Autor:innen

JPShamartomatous‐polyppediatric

Substanzen

Smad4 ProteinBone Morphogenetic Protein Receptors, Type IBMPR1A protein, humanSMAD4 protein, human

Autor:innen und Institutionen

  • Tel Aviv Sourasky Medical Center, affiliated to the Faculty of Medicine, Pediatric Gastroenterology Institute, Dana-Dwek Children's Hospital, Tel Aviv University, Tel Aviv, Israel.
  • Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Departments of Pediatrics and Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Department of Pediatrics, Division of Gastroenterology Hepatology and Nutrition, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Rambam Medical Center, Faculty of Medicine, Pediatric Gastroenterology and Nutrition Institute, Ruth Children's Hospital of Haifa, Technion, Haifa, Israel.
  • Department of Pediatric Gastroenterology, Hepatology and Nutrition, University Hospital Motol and 2nd Faculty of Medicine, Prague, Czech Republic.

ORCID-Profile: Shlomi Cohen

Förderung

  • ESPGHAN Networking Grant

Zitieren

APA

Cohen, S., Yerushalmy-Feler, A., Rojas, I., Phen, C., Rudnick, D. A., Flahive, C. B., Erdman, S. H., Magen-Rimon, R., Copova, I., Attard, T., Latchford, A., & Hyer, W. (2024). Juvenile polyposis syndrome in children: The impact of SMAD4 and BMPR1A mutations on clinical phenotype and polyp burden. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12257

Vancouver

Cohen S, Yerushalmy-Feler A, Rojas I, Phen C, Rudnick DA, Flahive CB, et al. Juvenile polyposis syndrome in children: The impact of SMAD4 and BMPR1A mutations on clinical phenotype and polyp burden. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12257

BibTeX
@article{Cohen2024,
  author = {Cohen, Shlomi and Yerushalmy-Feler, Anat and Rojas, Isabel and Phen, Claudia and Rudnick, David A and Flahive, Colleen B and Erdman, Steven H and Magen-Rimon, Ramit and Copova, Ivana and Attard, Thomas and Latchford, Andrew and Hyer, Warren},
  title = {Juvenile polyposis syndrome in children: The impact of SMAD4 and BMPR1A mutations on clinical phenotype and polyp burden},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2024},
  doi = {10.1002/jpn3.12257}
}
Kostenlos starten →